SAN FRANCISCO, May 15 (Xinhua) -- U.S. biotechnology company Genentech announced on Tuesday that it has been picked for a first- ever Alzheimer's disease prevention trial which may determine whether one of the company's experimental drugs could delay or prevent people with a genetic history to get the dementia.
According to the South San Francisco-headquartered company, the study will involve about 300 cognitively healthy people from local families in Medellin, Colombia. All of them can be traced to a common descendant and share a rare genetic mutation that typically triggers Alzheimer's symptoms around age 45. The study will also include a small number of participants in the United States./.../
|
http://www.nytimes.com/2012/05/16/health/research/prevention-is-goal-of-alzheimers-drug-trial.html?pagewanted=1&nl=todaysheadlines&emc=edit_th_20120516
No comments:
Post a Comment